Hypogonadism diagnostics, gonadotropins and replacement hormones - diagnosis and treatment options for endocrinologists

Keeping you up to date with the latest clinical trial information

Hypogonadism

Testosterone Replacement Therapy and Late-onset Hypogonadism
Late-onset hypogonadism (LOH) is a clinical and biochemical syndrome associated with advancing age and characterised by typical symptoms and a deficiency in serum testosterone levels.

T in Cheek: Buccal Testosterone as a New Treatment for Androgen Deficiency in Men
Male androgen deficiency has become a burgeoning area of public and commercial interest. Male androgen deficiency (commonly called male hypogonadism) is a common and important endocrinological syndrome defined by signs and symptoms of androgen deficiency plus low serum testosterone levels.

Investigation, Treatment and Monitoring of Late-onset Hypogonadism
Androgen deficiency in the ageing male (ADAM) has become a topic of much interest and debate.

Leuprolide in Treating Adults With Hypogonadotropism
Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.

Related Articles

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

Long-term effects of testim(r) 1% testosterone gel in hypogonadal men

Review of Testim gel

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men

Does Testosterone Improve Function in Hypogonadal Older Men
This is a randomized controlled trial of testosterone replacement therapy in hypogonadal men age > 60 years. The goal is to assess the safety and efficacy of TRT in men age > 60 years.

Related Articles

Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects

The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?

Testosterone supplementation therapy for older men: potential benefits and risks

ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale

Testosterone therapy--what, when and to whom?

Study of GnRH (Gonadotropin Releasing Hormone) Treatment for Idiopathic Hypogonadotropic Hypogonadism (IHH)
The purpose of the study is to provide treatment for idiopathic hypogonadotropic hypogonadism (IHH) and study how forms of IHH affect reproductive hormones. IHH is a disorder which results in a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain called the hypothalamus. When GnRH is released, it signals another gland in the brain, the pituitary, to secrete the reproductive hormones that influence testosterone levels and sperm production. In this study, men 18 and older with IHH have a detailed evaluation which involves an overnight study at the hospital. Some men may continue on to receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in IHH and results in normalized testosterone and typically is effective in developing fertility. The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).

Related Articles

Two novel mutations in the gonadotropin-releasing hormone receptor gene in Brazilian patients with hypogonadotropic hypogonadism and normal olfaction

Role of sequence variations of the GnRH receptor and G protein-coupled receptor 54 gene in male idiopathic hypogonadotropic hypogonadism

GNRHR mutations in a woman with idiopathic hypogonadotropic hypogonadism highlight the differential sensitivity of luteinizing hormone and follicle-stimulating hormone to gonadotropin-releasing hormone

Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism

Familial gonadotropin-releasing hormone resistance and hypogonadotropic hypogonadism in a family with multiple affected individuals

Newly FDA-approved drugs

Effexor XR (venlafaxine) Extended-Release Capsules
First Approved: October 20, 1997 Company: Wyeth Pharmaceuticals
Treatment for: Depression, GAD, Social Anxiety Disorder
Effexor XR is an extended-release serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant indicated for the treatment of major depressive disorder, generalized anxiety disorder (GAD) and social anxiety disorder.
New Indication Approved: November 18, 2005
Treatment for: Panic Disorder

Effexor XR is now approved for the treatment of adults with panic disorder, a condition characterized by recurrent, unexpected panic attacks.

http://www.drugs.com/pdr/effexor_xr_capsules.html

Venlafaxine extended-release: a review of its use in the management of major depression

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

Articles :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Companies :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Events :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Keywords :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Specialities :	Acromegaly Diabetes Diabetic Complications Erectile Dysfunction Female Sexual Dysfunction Growth Hormone Deficiency Hypogonadism Menopause & Hormone Replacement Therapy Thyroid disorders
Other Touch Group sites:	Cardiology - Endocrine Disease - Oncological Disease - Gastroenterology - Respiratory Disease